← Who reports today · Health Care
Merck (MRK) earnings date & Q3 2026 results
Net Income Attributable to Merck & Co., Inc.
$5,065M
down 12.4% y/y
Sales
$18,085M
up 4.7% y/y
Next report
~ Feb 2
not announced yet
The quarter in brief
Merck's Q3 2026 sales rose 5% to $18,085 million, but GAAP net income fell 12% to $5,065 million and diluted EPS dropped to $2.04 from $2.32. Higher costs, a $400 million license charge and a swing in other expense outweighed sales growth.
Key growth driver: KEYTRUDA/KEYTRUDA QLEX sales grew 6% to $8.6 billion, WINREVAIR rose 93% to $694 million and GARDASIL/GARDASIL 9 rose 14% to $1,995 million. · by the Q3 2026 report
- Net Income Attributable to Merck & Co., Inc. −12.4% — GAAP EPS fell on higher pipeline and launch spending, amortization, net interest and restructuring, partly offset by a lower tax rate
Source
«The decrease was primarily driven by higher operating expenses, reflecting increased investments to advance the R&D pipeline and support product launches, higher amortization of intangible assets, higher net interest expense and increased restructuring costs, partially offset by operational strength in the business and a lower effective income tax rate.»
press release, 8-K
All figures in $M.
| Line item | Amount and change |
|---|---|
| Sales | $18,085 · +4.7% |
| Cost of sales | $4,892 · +26.9% |
| Selling, general and administrative | $2,886 · +9.6% |
| Research and development | $4,537 · +7.2% |
| Restructuring costs | $184 · +291% |
| Other (income) expense, net | $27 · vs −$238 |
| Income Before Taxes | $5,559 · −17.6% · 30.7% margin |
| Income Tax Provision | $492 · −48.6% · 8.9% effective rate |
| Net Income Attributable to Noncontrolling Interests | $2 · +0.0% |
| Net Income Attributable to Merck & Co., Inc. | $5,065 · −12.4% · $2.04/sh · 28.0% margin |
Verdict: Merck's Q3 2026 sales rose 5% to $18,085 million, but GAAP net income fell 12% to $5,065 million and diluted EPS dropped to $2.04 from $2.32. Higher costs, a $400 million license charge and a swing in other expense outweighed sales growth.
Merck narrowed its full-year 2026 sales outlook to $66.8–67.3 billion from $66.3–67.3 billion. Non-GAAP EPS guidance was raised to $2.77–2.82 from $2.66–2.76, including one-time charges of $3.62 (Cidara), $2.31 (Terns) and $0.12 (SciBrunch) per share. The full-year non-GAAP tax rate outlook is now 32.0%–33.0% versus 35.0%–36.0% before.
Source and notation
Source: Merck & Co. earnings release, 8-K EX-99 of 10/29/2026 (SEC EDGAR).
Open as an image: Merck (MRK), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Merck (MRK) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/mrk. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/mrk"><img src="https://whoreportstoday.com/t/mrk/img/merck-and-co-mrk-earnings-sankey.png" alt="Merck (MRK) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/mrk">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/mrk/img/merck-and-co-mrk-earnings-sankey.png
<a href="https://whoreportstoday.com/t/mrk">Merck (MRK) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- KEYTRUDA/KEYTRUDA QLEX sales grew 6% to $8.6 billion, WINREVAIR rose 93% to $694 million and GARDASIL/GARDASIL 9 rose 14% to $1,995 million.
- R&D expenses rose 7% to $4,537 million, including a $400 million SciBrunch license charge ($0.12 per share), versus a $300 million LaNova milestone a year ago.
- Other (income) expense, net swung to $27 million of expense from $238 million of income.
- Restructuring costs line rose to $184 million from $47 million, and income before taxes fell 18% to $5,559 million.
- The effective tax rate dropped to 8.9% from 14.2%, cutting tax expense to $492 million from $958 million.
- Diluted share count fell to 2,478 million from 2,498 million.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Robert M. DavisChairman, Chief Executive Officer and President [1]
- Caroline LitchfieldExecutive Vice President, Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Mercksince 2016
- Chairman, Chief Executive Officer and Presidentsince 2022
- Chief Executive Officer and President2021–2022
- Executive Vice President, Global Services, and Chief Financial Officer2016–2021
Source: SEC EDGAR: 10-K annual report, 2026-02-24 · as of 10/21/2026
- Mercksince 2021Executive Vice President and Chief Financial Officer
Source: SEC EDGAR: 10-K annual report, 2026-02-24 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. · Text: Wikipedia, CC BY-SA 4.0, abridged
The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. Market share (US pharma & biotech): ≈9% by TTM revenue.
Heads-up
- net income fell 12% y/y in Q3 2026
Net income for Q3 2026: $5,065M, −12% y/y. In the report's figures: costs grew faster than revenue: cost of sales +27% y/y, restructuring costs +291% y/y. The company explains: GAAP EPS fell on higher pipeline and launch spending, amortization, net interest and restructuring, partly offset by a lower tax rate (press release, 8-K). Based on the Q3 2026 report.
The company's report ↗Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | revenue $66.8–67.3BEPS (non-GAAP) $2.77–2.82 | revenue $65BEPS (GAAP) $7.28 | revenue +3…4% |
Same quarter a year ago (ended December 31, 2025): revenue $16.4B, EPS (GAAP) $1.19
How we calculate
Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +3%).
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 29, 2026); every figure is checked against the release text.
MRK earnings history: past report dates
| Oct 29, 2026 Thu | 6:43 ambefore market open | Sep 30, 2026 | $18.1B+5% y/y | $2.04−12% y/y |
| Aug 4, 2026 Tue | 6:47 ambefore market open | Jun 30, 2026 | $16.6B+5% y/y | −$0.54 |
| Apr 30, 2026 Thu | 6:53 ambefore market open | Mar 31, 2026 | $16.3B+5% y/y | −$1.72 |
| Feb 3, 2026 Tue | 6:38 ambefore market open | Dec 31, 2025 | ≈$16.4B+5% y/y | ≈$1.19−20% y/y |
| Oct 30, 2025 Thu | 6:40 ambefore market open | Sep 30, 2025 | $17.3B+4% y/y | $2.32+87% y/y |
| Jul 29, 2025 Tue | 6:42 ambefore market open | Jun 30, 2025 | $15.8B−2% y/y | $1.76−18% y/y |
| Apr 24, 2025 Thu | 6:45 ambefore market open | Mar 31, 2025 | $15.5B−2% y/y | $2.01+7% y/y |
| Feb 4, 2025 Tue | 6:45 ambefore market open | Dec 31, 2024 | ≈$15.6B+7% y/y | ≈$1.49 |
| Oct 31, 2024 Thu | 6:44 ambefore market open | Sep 30, 2024 | $16.7B+4% y/y | $1.24−33% y/y |
| Jul 30, 2024 Tue | 6:41 ambefore market open | Jun 30, 2024 | $16.1B+7% y/y | $2.14 |
| Apr 25, 2024 Thu | 6:41 ambefore market open | Mar 31, 2024 | $15.8B+9% y/y | $1.87+68% y/y |
| Feb 1, 2024 Thu | 6:39 ambefore market open | Dec 31, 2023 | ≈$14.6B+6% y/y | ≈−$0.48 |
| Oct 26, 2023 Thu | 6:38 ambefore market open | Sep 30, 2023 | $16.0B+7% y/y | $1.86+45% y/y |
| Aug 1, 2023 Tue | 6:46 ambefore market open | Jun 30, 2023 | $15.0B+3% y/y | −$2.35 |
| Apr 27, 2023 Thu | 6:43 ambefore market open | Mar 31, 2023 | $14.5B−9% y/y | $1.11−35% y/y |
| Feb 2, 2023 Thu | 6:42 ambefore market open | Dec 31, 2022 | ≈$13.8B+2% y/y | ≈$1.18−20% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Merck: 15-year financials
| 2025 | 65,011 | 18,254 | 12,360 | 8,176 |
| 2024 | 64,168 | 17,117 | 18,096 | 7,840 |
| 2023 | 60,115 | 365 | 9,143 | 7,445 |
| 2022 | 59,283 | 14,519 | 14,707 | 7,012 |
| 2021 | 48,704 | 13,049 | 8,674 | 6,610 |
| 2020 | —* | 7,067 | 5,824 | 6,215 |
| 2019 | 39,121 | 9,843 | 10,071 | 5,695 |
| 2018 | 42,294 | 6,220 | 8,307 | 5,172 |
| 2017 | 40,122 | 2,394 | 4,563 | 5,167 |
| 2016 | 39,807 | 3,920 | 8,762 | 5,124 |
| 2015 | 39,498 | 4,442 | 11,255 | 5,117 |
| 2014 | 42,237 | 11,920 | 6,672 | 5,170 |
| 2013 | 44,033 | 4,404 | 10,106 | 5,157 |
| 2012 | 47,267 | 6,168 | 8,068 | 5,116 |
| 2011 | 48,047 | 6,272 | 10,660 | 4,691 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. “—*” in revenue: we don’t show that year’s revenue — the annual figure is more than 2% off the sum of the quarters, or the filing tags several revenue lines and the total can’t be pinned down. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Merck: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 136,866 | 52,606 | 49,300 | 14,565 | 43,516 | 28,327 |
| 2024 | 117,106 | 46,313 | 37,100 | 13,242 | 38,782 | 28,420 |
| 2023 | 106,675 | 37,581 | 35,100 | 6,841 | 32,168 | 25,694 |
| 2022 | 109,160 | 45,991 | 30,700 | 12,694 | 35,722 | 24,239 |
| 2021 | 105,694 | 38,184 | 33,100 | 8,096 | 30,266 | 23,872 |
| 2020 | 91,588 | 25,317 | 31,800 | 8,050 | 27,764 | 27,327 |
| 2019 | 84,397 | 25,907 | 26,300 | 9,676 | 27,483 | 22,220 |
| 2018 | 82,637 | 26,701 | 25,100 | 7,965 | 25,875 | 22,206 |
| 2017 | 87,872 | 34,336 | 24,353 | 6,092 | 24,766 | 18,614 |
| 2016 | 95,377 | 40,088 | 24,574 | 6,515 | 30,614 | 17,204 |
| 2015 | 101,677 | 44,676 | 26,129 | 8,524 | 29,751 | 19,201 |
| 2014 | 98,167 | 48,647 | 19,699 | 7,441 | 32,605 | 18,397 |
| 2013 | 105,645 | 49,765 | 22,639 | 15,621 | 35,685 | 17,868 |
| 2012 | 106,132 | 53,020 | 18,054 | 13,451 | 34,857 | 18,348 |
| 2011 | 105,128 | 54,517 | 17,515 | 13,531 | 33,181 | 16,245 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 15,846 | 13,615 | +2,231 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 1,906 | 1,552 | |
| · incl. stock-based comp (non-cash)share-based compensation | 852 | 615 | |
| Capexpurchases of property & equipment | −2,924 | −3,079 | +155 |
| Free cash flow ≈operating cash flow − capex | 12,922 | 10,536 | +2,386 |
| Investing activities, netcapex, acquisitions, securities | −17,131 | −2,540 | −14,591 |
| · incl. acquisitionsbusinesses net of cash acquired | −8,779 | 0 | −8,779 |
| Financing activities, netdebt, buybacks, dividends | −3,651 | −6,673 | +3,022 |
| · incl. buybacksrepurchases of common stock | −2,284 | −3,832 | +1,548 |
| · incl. dividends paid | −6,348 | −6,158 | −190 |
| FX effect on cash | −102 | 540 | −642 |
| Net change in cash | −5,038 | 4,942 | −9,980 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: $44.9B (34% of total assets). Compare with other S&P 500 companies →
Corporate governance
1.5/2mostly good
- Jan 2016Merck agreed to settle the Vioxx shareholder class action for $830M plus attorneys' fees (insurance covered about $380M). sec.gov ↗
- Feb 2013Merck will pay $215M and $473M (for Schering-Plough) to settle shareholder suits over the ENHANCE trial (Vytorin/Zetia). sec.gov ↗
2 more facts and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Feb 20262025 10-K: a single class of common stock; a new shareholder class action and derivative suits filed in 2025 are disclosed — not settled. sec.gov ↗
- Dec 2025Dividend per share rose from $2.48 (2020) to $3.28 (2025); share count −1.3% over 5 years. data.sec.gov ↗
Scoring: 2.0 −0.25 (criterion 9: Vioxx shareholder suit settled for $830M + attorneys' fees, January 2016, more than 10 years ago — half of 0.5) −0.25 (criterion 9: shareholder suit over the ENHANCE trial (Vytorin/Zetia) settled for $688M together with Schering-Plough, 2013, more than 10 years ago — half of 0.5) = 1.5
- Share classes
- Single class — MRK common stock on the NYSE (cover of 2025 10-K).
- Dilution
- Diluted share count 2020→2025 −1.3% (XBRL); SBC 1.3% of revenue.
- Disclosure
- Full 10-K/10-Q reporting.
- Dividends
- Dividend per share raised every year: $2.48 (2020) → $3.28 (2025); the Organon spin-off (2021) came without a dividend cut.
- Lawsuits & regulators
- Shareholder suits over Vioxx ($830M, 2016) and ENHANCE ($688M, 2013) were settled — both more than 10 years ago; the new 2025 class action and derivative suits are not settled — no deduction; no SEC disclosure cases.
- Related parties
- 2026 proxy: a related-party transaction policy is in place, no material transactions disclosed; no controlling shareholder.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Merck (MRK) earnings: FAQ
When is MRK's next earnings date?
We have not yet seen an announcement of the date from Merck (MRK). Based on last year's report on Feb 3, 2026, the next report is expected around Feb 2, 2027.
What time does MRK report earnings?
Merck usually reports before market open: its latest results release was filed with the SEC at 6:43 am ET on Oct 29, 2026.
When did MRK last report earnings?
Merck reported Q3 2026 results on Oct 29, 2026.
What has Merck guided for FY2026?
Company guidance for FY2026: revenue $66.8–67.3B; EPS (non-GAAP) $2.77–2.82. A year ago (FY2025): revenue $65B, EPS (GAAP) $7.28. Implied growth: revenue +3…4%. Source: the company's earnings release (Form 8-K filed Oct 29, 2026).
Where can I find Merck's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to MRK's filings; this page breaks the latest report down in a Sankey chart.
What was MRK's net income in Q3 2026?
Merck reported net income of $5,065M for Q3 2026 (−12.4% year over year), under US GAAP.
Does Merck pay dividends?
Yes. In 2025, Merck paid $8,176M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Merck's revenue changed since 2011?
Per its 10-K filings, revenue grew 1.4x: $48,047M in 2011 and $65,011M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q2 2026 · STE · Q2 FY2027 · SYK · Q3 2026 · all reports